Phenoxyalkylamine compound

Patent metadata

Field	Value
Publication number	US-9771316-B2
Application number	US-201414761897-A
Country	US
Kind code	B2
Filing date	Jan 21, 2014
Priority date	Jan 21, 2013
Publication date	Sep 26, 2017
Grant date	Sep 26, 2017

Abstract

The invention provides a compound having a selective inhibitory activity against highly-expressed LAT-1 in tumor cell. The compound is represented by the formula (I):

wherein each symbol is as defined in the specification, or a salt thereof, and a LAT-1 inhibitor comprising the same.

First claim

The invention claimed is:

1. A compound represented by the formula (I):

wherein
Ring A is an optionally substituted cyclic group,
Ring B is an optionally substituted cyclic group,
R 1 and R 2 are each independently a hydrogen atom, an optionally substituted alkyl group or an optionally substituted cycloalkyl group,
X is O, S, S(O), or S(O) 2 , and
n is an integer of 4 to 6,
or a salt thereof.

2. The compound or salt of claim 1 , wherein Ring A is a C 6-14 aryl group, an aromatic heterocyclic group or a non-aromatic heterocyclic group, each optionally substituted.

3. The compound or salt of claim 1 , wherein Ring A is optionally substituted phenyl.

4. The compound or salt of claim 1 , wherein Ring B is an optionally substituted aromatic group.

5. The compound or salt of claim 1 , wherein Ring B is phenyl or thienyl, each optionally substituted.

6. The compound or salt of claim 1 , wherein R 1 and R 2 are each independently a hydrogen atom or a C 1-6 alkyl group.

7. The compound or salt of claim 1 , wherein R 1 and R 2 are each independently a hydrogen atom or a C 1-3 alkyl group.

8. The compound or salt of claim 1 , wherein n is 4 or 5.

9. The compound or salt of claim 1 , wherein n is 4.

10. The compound or salt of claim 1 , wherein X is O.

11. A pharmaceutical composition comprising the compound or salt of claim 1 , and a pharmaceutically acceptable carrier.

12. A LAT-1 inhibitor comprising the compound or salt of claim 1 .

13. A method of treating cancer selected from the group consisting of pancreatic cancer, lung cancer, colorectal cancer, breast cancer, brain tumor, stomach cancer, liver cancer, esophageal cancer, head and neck cancer, and tongue cancer in a subject, comprising administering to the subject an effective amount of a compound represented by the formula (I):

wherein
Ring A is optionally substituted phenyl,
Ring B is optionally substituted phenyl,
R 1 and R 2 are each independently a hydrogen atom, an optionally substituted alkyl group or an optionally substituted cycloalkyl group,
X is O, and
n is an integer of 4 to 6,

or a salt thereof.

14. The method of claim 13 , wherein the cancer is pancreatic cancer or lung cancer.

15. A compound represented by the formula (12):

wherein
Ring A is an optionally substituted cyclic group,
Ring B is an optionally substituted cyclic group,
R 1 is a hydrogen atom, an optionally substituted alkyl group or an optionally substituted cycloalkyl group,
X 1 is O, S or NR 3 wherein R 3 is a hydrogen atom or an optionally substituted alkyl group, and
n is an integer of 4 to 6,
or a salt thereof.

16. The method of claim 13 , wherein the cancer is selected from the group consisting of colorectal cancer, breast cancer, brain tumor, stomach cancer, and liver cancer.

Assignees

• Univ Osaka
• Knc Laboratories Co Ltd

Inventors

• Kanai Yoshikatsu
• Nagamori Shushi
• Kitaura Yoshihiko
• Neya Masahiro
• Matsushita Naohiro

Classifications

• A61P35/00

  Antineoplastic agents · CPC title

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• C07D409/04

  directly linked by a ring-member-to-ring-member bond · CPC title

• C07D409/06

  linked by a carbon chain containing only aliphatic carbon atoms · CPC title

• A61P1/18

  for pancreatic disorders, e.g. pancreatic enzymes · CPC title